In addition to priming CD4+ T cells by peptide-MHC II complex, these tumour antigen-loaded DCs also elicit effective CD8+ T-cell anti-tumour response through cross-priming, a process in which DC presents the exogenous peptide by MHC I molecules to prime CD8+ T cells.71 This evidence concerns the gene CD8A and neoplasm.